- Home
- STEX vs ZNTL Comparison
STEX vs ZNTL Comparison
Compare STEX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEX | ZNTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.6M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | STEX | ZNTL |
|---|---|---|
| Price | $3.08 | $1.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $5.87 |
| AVG Volume (30 Days) | 739.4K | ★ 788.9K |
| Earning Date | 02-17-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,000.00 | ★ $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $1.01 |
| 52 Week High | $14.11 | $3.33 |
Technical Indicators
Market Signals| Indicator | STEX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.71 |
| Support Level | N/A | $1.31 |
| Resistance Level | N/A | $1.46 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 29.41 |
Price Performance
Historical ComparisonAbout STEX Streamex Corp.
Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.